Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Global Blood Ther (GBT)

Global Blood Ther (GBT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,742,673
  • Shares Outstanding, K 65,098
  • Annual Sales, $ 194,750 K
  • Annual Income, $ -303,090 K
  • 60-Month Beta 1.09
  • Price/Sales 9.14
  • Price/Cash Flow N/A
  • Price/Book 13.01
Trade GBT with:

Options Overview Details

View History
  • Implied Volatility 79.69% ( +3.61%)
  • Historical Volatility 75.47%
  • IV Percentile 73%
  • IV Rank 40.86%
  • IV High 135.51% on 11/01/21
  • IV Low 41.13% on 06/09/21
  • Put/Call Vol Ratio 0.08
  • Today's Volume 86
  • Volume Avg (30-Day) 186
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 13,072
  • Open Int (30-Day) 13,690

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.20
  • Number of Estimates 15
  • High Estimate -1.02
  • Low Estimate -1.45
  • Prior Year -1.12
  • Growth Rate Est. (year over year) -7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.67 +11.29%
on 05/11/22
35.20 -28.32%
on 04/26/22
-9.61 (-27.58%)
since 04/25/22
3-Month
22.67 +11.29%
on 05/11/22
38.05 -33.69%
on 04/05/22
-4.61 (-15.45%)
since 02/25/22
52-Week
22.67 +11.29%
on 05/11/22
41.73 -39.54%
on 06/09/21
-12.89 (-33.81%)
since 05/25/21

Most Recent Stories

More News
Why Global Blood Therapeutics Stock Was Sickly Today

The bears pounced on the company despite a first-quarter bottom-line beat.

GBT : 25.23 (-1.75%)
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

VRTX : 270.84 (+0.88%)
CLVS : 0.6695 (+6.25%)
GBT : 25.23 (-1.75%)
VYGR : 5.96 (-1.49%)
Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript

GBT earnings call for the period ending March 31, 2022.

GBT : 25.23 (-1.75%)
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

GBT : 25.23 (-1.75%)
RPTX : 8.96 (+1.36%)
GBT Reports First Quarter 2022 Financial Results

Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth...

GBT : 25.23 (-1.75%)
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report

Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity, Equity and Inclusion and Corporate...

GBT : 25.23 (-1.75%)
Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GBT : 25.23 (-1.75%)
GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1,...

GBT : 25.23 (-1.75%)
Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GBT : 25.23 (-1.75%)
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will...

GBT : 25.23 (-1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops treatments for underserved patient communities.

See More

Key Turning Points

3rd Resistance Point 27.44
2nd Resistance Point 26.70
1st Resistance Point 25.97
Last Price 25.23
1st Support Level 24.50
2nd Support Level 23.76
3rd Support Level 23.03

See More

52-Week High 41.73
Fibonacci 61.8% 34.45
Fibonacci 50% 32.20
Fibonacci 38.2% 29.95
Last Price 25.23
52-Week Low 22.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar